129 related articles for article (PubMed ID: 26617196)
1. Pharmacokinetic/pharmaco-dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on Δ(9)-tetrahydrocannabinol challenge tests.
Guan Z; Klumpers LE; Oyetayo OO; Heuberger J; van Gerven JM; Stevens J
Br J Clin Pharmacol; 2016 Apr; 81(4):713-23. PubMed ID: 26617196
[TBL] [Abstract][Full Text] [Related]
2. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects.
Klumpers LE; Fridberg M; de Kam ML; Little PB; Jensen NO; Kleinloog HD; Elling CE; van Gerven JM
Br J Clin Pharmacol; 2013 Dec; 76(6):846-57. PubMed ID: 23601084
[TBL] [Abstract][Full Text] [Related]
3. Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.
Klumpers LE; Roy C; Ferron G; Turpault S; Poitiers F; Pinquier JL; van Hasselt JG; Zuurman L; Erwich FA; van Gerven JM
Br J Clin Pharmacol; 2013 Jul; 76(1):65-77. PubMed ID: 23278647
[TBL] [Abstract][Full Text] [Related]
4. Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats.
Järbe TU; Liu Q; Makriyannis A
Psychopharmacology (Berl); 2006 Jan; 184(1):36-45. PubMed ID: 16307294
[TBL] [Abstract][Full Text] [Related]
5. Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease.
Carroll CB; Zeissler ML; Hanemann CO; Zajicek JP
Neuropathol Appl Neurobiol; 2012 Oct; 38(6):535-47. PubMed ID: 22236282
[TBL] [Abstract][Full Text] [Related]
6. Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats.
Calik MW; Carley DW
Sleep; 2017 Sep; 40(9):. PubMed ID: 28934522
[TBL] [Abstract][Full Text] [Related]
7. Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.
Klumpers LE; Beumer TL; van Hasselt JG; Lipplaa A; Karger LB; Kleinloog HD; Freijer JI; de Kam ML; van Gerven JM
Br J Clin Pharmacol; 2012 Jul; 74(1):42-53. PubMed ID: 22680341
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625.
Zuurman L; Roy C; Schoemaker RC; Amatsaleh A; Guimaeres L; Pinquier JL; Cohen AF; van Gerven JM
J Psychopharmacol; 2010 Mar; 24(3):363-71. PubMed ID: 18801827
[TBL] [Abstract][Full Text] [Related]
9. Modelling of the concentration--effect relationship of THC on central nervous system parameters and heart rate -- insight into its mechanisms of action and a tool for clinical research and development of cannabinoids.
Strougo A; Zuurman L; Roy C; Pinquier JL; van Gerven JM; Cohen AF; Schoemaker RC
J Psychopharmacol; 2008 Sep; 22(7):717-26. PubMed ID: 18583433
[TBL] [Abstract][Full Text] [Related]
10. Delta9-THC induced hyperphagia and tolerance assessment: interactions between the CB1 receptor agonist delta9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats.
Järbe TU; DiPatrizio NV
Behav Pharmacol; 2005 Sep; 16(5-6):373-80. PubMed ID: 16148441
[TBL] [Abstract][Full Text] [Related]
11. Sex, THC, and hormones: Effects on density and sensitivity of CB
Farquhar CE; Breivogel CS; Gamage TF; Gay EA; Thomas BF; Craft RM; Wiley JL
Drug Alcohol Depend; 2019 Jan; 194():20-27. PubMed ID: 30391834
[TBL] [Abstract][Full Text] [Related]
12. Exploring the Ligand Efficacy of Cannabinoid Receptor 1 (CB1) using Molecular Dynamics Simulations.
Jung SW; Cho AE; Yu W
Sci Rep; 2018 Sep; 8(1):13787. PubMed ID: 30213978
[TBL] [Abstract][Full Text] [Related]
13. Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys.
Schindler CW; Redhi GH; Vemuri K; Makriyannis A; Le Foll B; Bergman J; Goldberg SR; Justinova Z
Neuropsychopharmacology; 2016 Aug; 41(9):2283-93. PubMed ID: 26888056
[TBL] [Abstract][Full Text] [Related]
14. Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers.
Tudge L; Williams C; Cowen PJ; McCabe C
Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25542687
[TBL] [Abstract][Full Text] [Related]
15. Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling.
Liu Z; Martin JH
Br J Clin Pharmacol; 2018 Nov; 84(11):2483-2487. PubMed ID: 29766540
[TBL] [Abstract][Full Text] [Related]
16. Biphasic effects of Δ9-tetrahydrocannabinol on brain stimulation reward and motor activity.
Katsidoni V; Kastellakis A; Panagis G
Int J Neuropsychopharmacol; 2013 Nov; 16(10):2273-84. PubMed ID: 23830148
[TBL] [Abstract][Full Text] [Related]
17. Crystal Structure of the Human Cannabinoid Receptor CB
Hua T; Vemuri K; Pu M; Qu L; Han GW; Wu Y; Zhao S; Shui W; Li S; Korde A; Laprairie RB; Stahl EL; Ho JH; Zvonok N; Zhou H; Kufareva I; Wu B; Zhao Q; Hanson MA; Bohn LM; Makriyannis A; Stevens RC; Liu ZJ
Cell; 2016 Oct; 167(3):750-762.e14. PubMed ID: 27768894
[TBL] [Abstract][Full Text] [Related]
18. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
Craft RM; Wakley AA; Tsutsui KT; Laggart JD
J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
[TBL] [Abstract][Full Text] [Related]
19. Contrasting effects of different cannabinoid receptor ligands on mouse ingestive behaviour.
Grey J; Terry P; Higgs S
Behav Pharmacol; 2012 Sep; 23(5-6):551-9. PubMed ID: 22772336
[TBL] [Abstract][Full Text] [Related]
20. Δ(9)-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice.
Paronis CA; Nikas SP; Shukla VG; Makriyannis A
Behav Pharmacol; 2012 Dec; 23(8):802-5. PubMed ID: 23075707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
